Latigo Biotherapeutics, Inc. (LTGO) — real insider trading activity disclosed to the SEC, tracked automatically as new Form 4 filings are reported. Most recent: Foresite Capital Management V, LLC disclosed a transaction on 2026-08-10 worth $2,520,000.
Transactions disclosed by company insiders to the SEC on Form 4, most recent first.
| Insider | Role | Date | Shares | Value |
|---|---|---|---|---|
| 5AM Ventures VI, L.P. | Insider | 2026-08-10 | 4,975,543 | $0 |
| 5AM Ventures VI, L.P. | Insider | 2026-08-10 | 2,350,419 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 938,979 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 3,547,842 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 1,027,635 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 3,464,072 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 1,484,401 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 165,519 | $0 |
| Westlake BioPartners Fund I, L.P. | Insider | 2026-08-10 | 2,066,857 | $0 |
| SEIDENBERG BETH C | Insider | 2026-08-10 | 938,979 | $0 |
Data compiled from public SEC filings. This is informational reporting, not investment advice.
Foresite Capital Management V, LLC, a 10%+ owner of Latigo Biotherapeutics, Inc. (LTGO), disclosed an open-market purchase of 140,000 shares on August 10, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at $18.00 apiece, for a total transaction value of $2,520,000.00. This was a straightforward open-market … Read more
A newly filed Form 4 shows James B. Tananbaum, an insider at Latigo Biotherapeutics, Inc. (LTGO), purchased 140,000 shares of the company on the open market on August 10, 2026. The transaction was executed at $18.00 per share, for a total outlay of $2,520,000.00 out of the insider’s own funds. Unlike option exercises or grants … Read more